Results 71 to 80 of about 15,170 (273)
, 2023 <p>A general structure of an <a href='\"https://adc.bocsci.com/\"'>antibody-drug conjugate</a> contains a humanized/human monoclonal antibody (mAb), a cleavable/non-cleavable chemical linker, and a cytotoxic payload.
Linna, Green
core +1 more source
Frontiers in PharmacologyUrothelial carcinoma (UC) is a common cancer characterized by high morbidity and mortality rates. Despite advancements in treatment, challenges such as recurrence and low response rates persist. Antibody-drug conjugates (ADCs) have emerged as a promising
Chia-Hsien Shih +8 more
doaj +1 more source
Advanced Materials, EarlyView.Clinically, intermittent hypoxia (IH) is often accompanied by periodontitis, which accelerates cognitive impairment induced by IH. Novel Janus mesoporous gold‐silica nanoformulations (RVG‐Au&mSiO2‐TPP‐VB) enable intranasal delivery, achieve hierarchical targeting to neuronal mitochondria, effectively scavenge reactive oxygen species, inhibit the HIF‐1α/
Kai‐Run Zhang +15 more
wiley +1 more source
A mechanistic tumor penetration model to guide antibody drug conjugate design. [PDF]
PLoS ONE, 2015 Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens.
Christina Vasalou +2 more
doaj +1 more source
Advanced Materials, EarlyView.Fully recombinant protein‐based biomaterials execute complex Boolean logic for user‐programmable material degradation and concomitant therapeutic cargo release. Biologics, such as growth factors, can be incorporated within the crosslinkers as “drugamers”, while encapsulated cells can be released according to nested YES/OR/AND‐type logical operations ...
Murial L. Ross +3 more
wiley +1 more source
Hematology/Oncology and Stem Cell TherapyThe concept of a “magic bullet” in oncology—first envisioned by Paul Ehrlich—has evolved into one of the most dynamic areas in precision cancer therapeutics: antibody–drug conjugates (ADCs).
Roberto Paz-Manrique +2 more
doaj +1 more source
Recent Advances in Ferrite‐Based Materials for Biomedical Applications: A Comprehensive Review
Advanced Materials, EarlyView.Ferrite nanoplatforms are presented as tunable biomedical materials in which synthesis control, cation engineering, defect/morphology regulation, and surface functionalization govern structure–property–bioactivity relationships. These design strategies enable multifunctional applications including MRI contrast, magnetic hyperthermia, targeted drug ...
Pramod D. Mhase +6 more
wiley +1 more source
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
PharmaceuticsAntibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on
Youngbo Choi, Youbeen Choi, Surin Hong
doaj +1 more source
Trojan horses at leptomeningeal cellular gates: Antibody–drug conjugates deliver cytotoxic payloads
MedThe DEBBRAH study showed promising results for patients with HER2-expressing (including HER2-low) metastatic breast cancer who received the antibody-drug conjugate (ADC) trastuzumab deruxtecan for leptomeningeal disease. ADCs represent a novel tool in the precision biomarker-based armamentarium, including in the tumor-agnostic setting, for targeting ...
Nikanjam, Mina, Kurzrock, Razelle
openaire +2 more sources
From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates
Advanced Materials, EarlyView.Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot +3 more
wiley +1 more source